Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as a significant yet frequently overlooked etiology of heart failure, particularly within the elderly population. Recent epidemiological data reveal that up to 13% of older adults hospitalized with heart failure characterized by preserved ejection fraction may harbor this infiltrative cardiomyopathy. Despite its growing recognition, ATTR-CM remains underdiagnosed in routine clinical practice, resulting in missed opportunities for timely intervention and optimized patient care.
Addressing this diagnostic gap, the American Heart Association (AHA) has initiated a groundbreaking multicenter cluster randomized trial named TTRANSLATE-ATTR. This pioneering study is designed to rigorously evaluate whether a structured, provider-focused educational intervention can effectively enhance both the rates of diagnostic testing for ATTR-CM and the subsequent confirmed diagnoses among patients hospitalized with heart failure. The trial’s strategic embedding within the AHA’s Get With The Guidelines® – Heart Failure quality improvement program provides an unprecedented platform to assess the impact of targeted education in real-world hospital environments.